Marksans Pharma Limited
NSE:MARKSANS.NS
300.5 (INR) • At close November 12, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) INR.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 21,774.07 | 18,521.39 | 14,801.24 | 13,683.734 | 11,293.349 | 9,873.323 | 9,126.92 | 7,671.613 | 8,933.262 | 7,966.876 | 6,299.969 | 4,384.224 | 3,555.487 | 3,053.18 | 3,593.658 | 3,601.31 | 2,639.406 | 2,419.937 | 2,974.072 | 2,528.956 |
| Cost of Revenue
| 14,060.32 | 9,213.58 | 7,480.16 | 6,185.966 | 5,683.368 | 5,174.932 | 5,481.849 | 4,720.168 | 5,096.944 | 4,454.385 | 3,679.293 | 2,528.646 | 2,129.265 | 2,375.325 | 2,941.715 | 2,866.61 | 2,001.811 | 1,967.399 | 2,291.534 | 1,886.939 |
| Gross Profit
| 7,713.75 | 9,307.81 | 7,321.08 | 7,497.768 | 5,609.981 | 4,698.391 | 3,645.071 | 2,951.446 | 3,836.318 | 3,512.491 | 2,620.676 | 1,855.578 | 1,426.223 | 677.855 | 651.943 | 734.7 | 637.594 | 452.538 | 682.538 | 642.016 |
| Gross Profit Ratio
| 0.354 | 0.503 | 0.495 | 0.548 | 0.497 | 0.476 | 0.399 | 0.385 | 0.429 | 0.441 | 0.416 | 0.423 | 0.401 | 0.222 | 0.181 | 0.204 | 0.242 | 0.187 | 0.229 | 0.254 |
| Reseach & Development Expenses
| 199.32 | 158.89 | 192.5 | 128.66 | 83.147 | 57.125 | 52.659 | 45.309 | 76.81 | 171.983 | 0 | 45.377 | 0 | 0 | 0 | 0 | 0 | 54.184 | 50.041 | 46.732 |
| General & Administrative Expenses
| 0 | 162.62 | 247.99 | 238.83 | 179.657 | 232.048 | 206.298 | 192.034 | 214.54 | 0 | 74.118 | 57.314 | 0 | 526.228 | 407.474 | 442.363 | 315.781 | 241.322 | 190.45 | 167.476 |
| Selling & Marketing Expenses
| 0 | 1,025.34 | 1,494.5 | 1,096.115 | 792.596 | 666.306 | 475.899 | 236.784 | 99.129 | 0 | 267.644 | 223.267 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 3,870.68 | 2,520.75 | 1,742.49 | 1,334.945 | 972.253 | 898.354 | 682.197 | 428.818 | 313.668 | 757.77 | 1,090.942 | 915.214 | 0 | 526.228 | 407.474 | 442.363 | 315.781 | 241.322 | 190.45 | 167.476 |
| Other Expenses
| 504.22 | 593.13 | 95.62 | 38.734 | 1.502 | 0.904 | 1.993 | 2,498.373 | 2,479.701 | 1,825.955 | 1,599.47 | 1,309.217 | 2,640.505 | 184.167 | 139.095 | 78.947 | 35.668 | -23.495 | 33.361 | 53.134 |
| Operating Expenses
| 3,870.68 | 6,433.13 | 5,153.72 | 4,310.634 | 3,953.05 | 3,605.043 | 3,129.083 | 2,927.19 | 2,793.369 | 1,825.955 | 1,599.47 | 1,309.217 | 2,640.505 | 710.395 | 546.569 | 521.311 | 351.449 | 272.01 | 273.851 | 267.342 |
| Operating Income
| 3,843.07 | 2,877.32 | 2,141.04 | 3,092.2 | 1,702.386 | 1,093.348 | 515.989 | 155.293 | 1,068.507 | 1,558.844 | 864.114 | 435.473 | -1,214.282 | -32.539 | 105.374 | 213.389 | 286.145 | 180.528 | 314.061 | 250.678 |
| Operating Income Ratio
| 0.176 | 0.155 | 0.145 | 0.226 | 0.151 | 0.111 | 0.057 | 0.02 | 0.12 | 0.196 | 0.137 | 0.099 | -0.342 | -0.011 | 0.029 | 0.059 | 0.108 | 0.075 | 0.106 | 0.099 |
| Total Other Income Expenses Net
| -3,556.33 | -3,062.18 | -2,694.83 | 34.78 | -46.108 | -50.283 | -18.008 | -6.32 | -1,306.068 | -947.425 | -373.327 | 0 | -535.754 | -1,319.731 | -197.639 | -283.381 | -81.016 | -87.241 | -0 | -101.732 |
| Income Before Tax
| 4,235.26 | 3,376.53 | 2,475.11 | 3,021.641 | 1,571.718 | 1,043.066 | 497.981 | 155.293 | 1,068.507 | 1,558.844 | 864.114 | 435.473 | -1,750.036 | -2,154.438 | -92.266 | -69.992 | 205.129 | 93.287 | 314.061 | 250.678 |
| Income Before Tax Ratio
| 0.195 | 0.182 | 0.167 | 0.221 | 0.139 | 0.106 | 0.055 | 0.02 | 0.12 | 0.196 | 0.137 | 0.099 | -0.492 | -0.706 | -0.026 | -0.019 | 0.078 | 0.039 | 0.106 | 0.099 |
| Income Tax Expense
| 1,086.31 | 723.32 | 606.97 | 636.253 | 364.191 | 238.695 | 139.971 | 35.149 | 241.076 | 439.209 | 127.87 | -52.789 | 10.757 | 64.136 | 3.951 | 9.556 | 47.943 | 26.357 | 85.147 | 45.092 |
| Net Income
| 3,137 | 2,663.08 | 1,845.69 | 2,385.38 | 1,207.527 | 804.371 | 329.4 | 95.188 | 785.116 | 1,093.965 | 719.077 | 458.843 | -1,788.397 | -2,232.444 | -100.434 | -83.554 | 157.186 | 66.93 | 228.914 | 205.585 |
| Net Income Ratio
| 0.144 | 0.144 | 0.125 | 0.174 | 0.107 | 0.081 | 0.036 | 0.012 | 0.088 | 0.137 | 0.114 | 0.105 | -0.503 | -0.731 | -0.028 | -0.023 | 0.06 | 0.028 | 0.077 | 0.081 |
| EPS
| 6.92 | 6.41 | 4.51 | 5.76 | 2.86 | 1.97 | 0.8 | 0.22 | 1.92 | 2.67 | 1.87 | 1.19 | -4.86 | -6.07 | -0.27 | -0.23 | 0.43 | 0.19 | 0.64 | 0.5 |
| EPS Diluted
| 6.92 | 6.41 | 4.51 | 5.76 | 2.86 | 1.97 | 0.8 | 0.22 | 1.92 | 2.67 | 1.87 | 1.19 | -4.64 | -6.07 | -0.27 | -0.23 | 0.43 | 0.19 | 0.64 | 0.5 |
| EBITDA
| 4,585.77 | 3,986.34 | 3,007.33 | 3,463.01 | 1,925.797 | 1,367.659 | 868.567 | 329.192 | 1,451.329 | 1,759.149 | 1,139.544 | 706.5 | -997.407 | -913.681 | 254.791 | 297.147 | 416.534 | 281.574 | 444.988 | 379.465 |
| EBITDA Ratio
| 0.211 | 0.215 | 0.199 | 0.259 | 0.167 | 0.135 | 0.091 | 0.065 | 0.158 | 0.227 | 0.187 | 0.16 | -0.275 | -0.017 | 0.071 | 0.083 | 0.158 | 0.116 | 0.153 | 0.152 |